As of April 19, 2025, Cassava Sciences (SAVA) has a market cap of $69.563 million USD. According to our data, Cassava Sciences is ranked No.7844 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 19, 2025 | $69.56 M |
-38.73%
|
Dec 31, 2024 | $0.11 B |
-89.52%
|
Dec 29, 2023 | $1.08 B |
-23.80%
|
Dec 30, 2022 | $1.42 B |
-32.40%
|
Dec 31, 2021 | $2.10 B |
540.76%
|
Dec 31, 2020 | $0.33 B |
31.15%
|
Dec 31, 2019 | $0.25 B |
511.76%
|
Dec 31, 2018 | $40.89 M |
-78.75%
|
Dec 29, 2017 | $0.19 B |
0.25%
|
Dec 30, 2016 | $0.19 B |
-67.43%
|
Dec 31, 2015 | $0.59 B |
-13.79%
|
Dec 31, 2014 | $0.68 B |
-58.23%
|
Dec 31, 2013 | $1.64 B |
79.34%
|
Dec 31, 2012 | $0.91 B |
-6.76%
|
Dec 30, 2011 | $0.98 B |
-43.70%
|
Dec 31, 2010 | $1.74 B |
65.29%
|
Dec 31, 2009 | $1.05 B |
-9.46%
|
Dec 31, 2008 | $1.16 B |
-44.15%
|
Dec 31, 2007 | $2.08 B |
19.10%
|
Dec 29, 2006 | $1.75 B |
31.66%
|
Dec 30, 2005 | $1.33 B |
-6.24%
|
Dec 31, 2004 | $1.42 B |
3.74%
|
Dec 31, 2003 | $1.36 B |
190.80%
|
Dec 31, 2002 | $0.47 B |
-73.91%
|
Dec 31, 2001 | $1.80 B |
-38.42%
|
Dec 29, 2000 | $2.92 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Biogen
BIIB
|
$17.36 B |
-0.001 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$754.27 B |
0.008 M
|
![]() USA
|
![]() AC Immune
ACIU
|
$0.15 B |
-0.000 M
|
![]() Switzerland
|
![]() Anavex Life Sciences
AVXL
|
$0.76 B |
-0.000 M
|
![]() USA
|
![]() Denali Therapeutics
DNLI
|
$1.85 B |
0.000 M
|
![]() USA
|
![]() Prothena
PRTA
|
$0.50 B |
-0.000 M
|
![]() Ireland
|
![]() BioXcel Therapeutics
BTAI
|
$9.51 M |
0.000 M
|
![]() USA
|
![]() Intra-Cellular Therapies
ITCI
|
$14.05 B |
0.000 M
|
![]() USA
|
![]() Sage Therapeutics
SAGE
|
$0.46 B |
-0.000 M
|
![]() USA
|
![]() ACADIA Pharmaceuticals
ACAD
|
$2.46 B |
0.000 M
|
![]() USA
|
![]() Alector
ALEC
|
$91.17 M |
0.010 M
|
![]() USA
|
Market Cap | = | SAVA Stock Price | * | SAVA Shares Outstanding |
= | $1.44 | * | 48.31 M | |
= | $69.56 M |